… safety of erlotinib for non-small cell lung cancer (NSCLC), we performed a population-based
observational study. The study involved 307 patients treated with erlotinib … received erlotinib …

… was designed to assess the safety and efficacy of erlotinib compared with chemotherapy
in … -doublet chemotherapy and who therefore had very poor prognosis (panel). Because of …

… Rash and diarrhea were more common in the erlotinib group (47.7% with erlotinib vs 43.2%
with placebo). This study concluded that erlotinib combined with carboplatin/paclitaxel …

… Non-small cell lung cancer (NSCLC) has a poor prognosis despite conventional treatments
of surgery, radiotherapy, and chemotherapy. Small-molecule tyrosine kinase inhibitors acting …

… Purpose To evaluate the efficacy and safety of erlotinib in advanced breast cancer.
Experimental design Multicenter, phase II study of erlotinib (150 mg orally daily). Cohort 1: …

… to be strong prognostic factors, but neither was predictive of a differential survival benefit with
erlotinib … had a statistically significant survival benefit from erlotinib, compared with placebo. …

… to improve the poor prognosis of patients with advanced pancreatic cancer. Erlotinib was
the … to explore the efficacy and safety of the combination of gemcitabine with erlotinib (GemErlo) …

… concomitant honeycombing with interstitial pneumonia as poor prognostic factors for ILD
death in … (n = 12) had a high risk of poor prognosis, regardless of their CT pattern. Therefore, …

… rate and safety profile of erlotinib HCl (erlotinib, Tarceva™, OSI-… Thirty-four patients received
150 mg erlotinib orally once daily … Erlotinib was generally well tolerated. The most frequent …

… %) and has been associated with poor prognosis [35]. The efficacy and safety of erlotinib in
patients with refractory, … Erlotinib had marginal activity but was generally well tolerated. The …